CTRI/2023/07/055523尚未招募3 期
Trastuzumab plus chemotherapy vs Chemotherapy alone in first-line HER2 positive advanced biliary tract cancer patients - a randomized non-blinded two-arm Phase III prospective clinical trial. - NI
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Histologically confirmed adenocarcinoma of the biliary tract, with the following specifications
- •2.HER2 positive (by IHC or FISH) unresectable or metastatic Biliary tract cancers.
- •3.Age more than or equal to 18 years, ECOG performance status 0 to 2.
- •4.Patient does not have any contraindications to receive chemotherapy or trastuzumab.
- •5.Adequate hematological, hepatic, and renal function parameters
- •6.Normal cardiac ejection fraction and cardiac function, as assessed by echocardiography, ejection fraction (EF) more than or equal to 50% or above the lower limit of normal. ECG with no clinically relevant abnormalities.
- •7.Women of childbearing age should have a negative pregnancy test at the time of randomization and should be willing to use adequate contraception during the treatment phase of the trial.
- •8.Subjects must provide written informed consent prior to the performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow-up assessments and procedures.
- •9.Subjects who have received adjuvant chemotherapy will be considered eligible provided that therapy is completed more than 12 months before study enrollment. Patients who have received radiation therapy and surgery will also be eligible provided the interventions have been completed 3 weeks, before enrolment in the study.
- •10.Negative serum pregnancy test (if applicable) and willing for adequate contraception.
- •11.At least one measurable disease according to RECIST criteria.
- •12.A life expectancy of at least 12 weeks.
排除标准
- •1.Distal cholangiocarcinoma
- •2.Known hypersensitivity or contraindications against gemcitabine, cisplatin, Nab-paclitaxel, or trastuzumab.
- •3.Clinically significant active coronary heart disease, cardiomyopathy, or congestive heart failure, NYHA III to IV.
- •4.Clinically significant valvular defect.
- •5.Past or current history of other malignancies not curatively treated and without evidence of disease for more than 5 years, except for curatively treated basal cell carcinoma of the skin and in situ carcinoma of the cervix.
- •6.Severe dyspnea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy.
- •7.Baseline neuropathy greater than NCI Grade I.
- •8.Subject pregnant or breastfeeding, or planning to become pregnant within 6 months after the end of treatment.
- •9.Received prior chemotherapy within 1 year.
- •10.Any active ILD or history of lung illness requiring bronchodilator drugs.
- •11.Patients with prior chemotherapy for metastatic disease will be ineligible for enrollment in the study.
研究者
相似试验
已完成
3 期
Evaluation of Trastuzumab without Chemotherapy as a Postoperative Adjuvant Therapy in HER2 Positive Elderly Breast Cancer Patients: Randomized Controlled TrialHER2 positive primary breast cancer in elderlyJPRN-UMIN000002349RESPECT executive committee275
进行中（未招募）
1 期
Chemotherapy plus Lapatinib (GW572016) or Trastuzumab or both in HER2+ Primary Breast Cancer. A Randomized Phase IIb study with Biomarker Evaluation - CHERLOBEUCTR2006-001839-21-GBGlaxoSmithKline Research and Development Limited
进行中（未招募）
不适用
A Randomized Phase IIb Study With Biomarker Evaluation (Cherlob) To Evaluate The Activity Of Different Combinations Of Lapatinib With Other Pre-Surgery Chemotherapy In Her2 Positive Operable Breast CancerEUCTR2006-001839-21-DEGlaxoSmithKline Reseacrh and Development Limited120
进行中（未招募）
1 期
Activity of trastuzumab based chemotherapy in metastatic breast patients with HER2-negative primary tumor but HER2 positive circulating tumor cells (CareMore-Trastuzumab)EUCTR2014-004432-18-NLErasmus MC Cancer Institute37
已完成
2 期
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast CancerNeoplasms, BreastNCT00429299GlaxoSmithKline121